KALAMAZOO, Mich., March 22, 2018 /PRNewswire/ -- Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of theAsepticSure® system, today announced the initiation of a Product Evaluation Agreement (the "Agreement") with Innovasource, LLC, a leading manufacturer of cleaning, deodorizing and disinfecting products ("Innovasource").
The Product Evaluation Agreement builds on a relationship between Innovasource and Medizone that commenced with the previously announced execution by the two companies of a Sales Representative Agreement in April 2017 and a Supply and License Agreement in October 2017. Pursuant to the Sales Representative Agreement, Medizone authorized Innovasource to solicit sales of the AsepticSure® Disinfection System to specified major accounts and agreed to pay Innovasource a commission on the net receipts from such sales. The Agreement will augment Innovasource's efforts to sell the AsepticSure® system to such accounts.
Medizone's CEO, David A. Dodd, commented, "This agreement is consistent with our recent commercial roll-out of AsepticSure®, focused on ensuring that AsepticSure® is utilized and validated in real-world settings. Innovasource is proving to be an excellent strategic partner for us. By demonstrating the AsepticSure® system to their existing customer base, we will gain real-world experience with the system while highlighting its very positive attributes to a wide base of potential customers. Such activity is critical and necessary for eventual AsepticSure® adoption throughout various markets. As a critical initial step, we feel that this Agreement is a real win-win for both parties."
Commenting on the Agreement, Innovasource President & CEO, Glenn Cueman, noted, "We have been increasingly impressed with the scientific validation in support of AsepticSure® and the potential to provide this technology as a distinct improvement in the disinfecting and cleaning of non-porous hard surfaces, across various markets. We look forward to proceeding with this Agreement, introducing AsepticSure® to a variety of different, yet important customers who will clearly benefit from use of this advance in disinfecting/cleaning technology, consistently providing an unprecedented 6-log kill of viruses, bacteria and other pathogens."
About Medizone International, Inc.
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H2O2) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.
About Innovasource LLC
Innovasource develops and markets environmentally-sustainable products for consumers and businesses. The company was founded in 2007 by a seasoned team with more than fifty years' experience in regulated product and consumer packaged goods. Innovasource's headquarters are in the Charlotte metropolitan region in Huntersville, North Carolina. For more information, go to: www.innovasource.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media RelationsMedizone International, Inc.T: 01 269-202-5020E: firstname.lastname@example.org
For more information, visit:www.medizoneint.comEmail: email@example.com
View original content:http://www.prnewswire.com/news-releases/medizone-international-and-innovasource-initiate-exclusive-asepticsure-product-evaluation-agreement-300618130.html
SOURCE Medizone International, Inc.
Subscribe to our Free Newsletters!
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...View All